SHANDONG SITO BIO-TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.59 CNY | -6.65% |
|
+5.98% | -21.18% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 1.4B 194M | Sales 2025 * | 1.54B 213M | Capitalization | 2.96B 409M |
|---|---|---|---|---|---|
| Net income 2024 * | 57M 7.89M | Net income 2025 * | 73M 10.1M | EV / Sales 2024 * | 2.11 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.92 x |
| P/E ratio 2024 * |
52
x | P/E ratio 2025 * |
40
x | Employees | 1,317 |
| Yield 2024 * |
0.06% | Yield 2025 * |
0.13% | Free-Float | 37.69% |
More Fundamentals
* Assessed data
More news
| 1 day | -6.65% | ||
| 1 week | +5.98% | ||
| Current month | +5.98% | ||
| 1 month | +3.31% | ||
| 3 months | +4.00% | ||
| 6 months | -24.14% | ||
| Current year | -21.18% |
1 week
14.78
18.98
1 month
11.9418.98
Current year
11.9420.90
1 year
11.9423.84
3 years
11.2623.84
5 years
11.0323.84
10 years
11.0358.39
| Managers | Title | Age | Since |
|---|---|---|---|
Qi Mi
CHM | Chairman | 34 | 19-01-15 |
Fu Wen Li
DFI | Director of Finance/CFO | 48 | 12-12-31 |
Lu Li
BRD | Director/Board Member | 47 | 19-01-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xu Sheng Kong
BRD | Director/Board Member | 63 | 20-11-15 |
Lu Li
BRD | Director/Board Member | 47 | 19-01-15 |
Ya Ping Ma
BRD | Director/Board Member | 50 | 20-11-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 15.59 | -6.65% | 17,690,650 |
| 24-05-09 | 16.7 | -2.57% | 21,547,990 |
| 24-05-08 | 17.14 | +5.41% | 15,505,070 |
| 24-05-07 | 16.26 | +5.11% | 12,814,550 |
End-of-day quote Shenzhen S.E., May 09, 2024
More quotes
Shandong Sito Bio-technology Co Ltd is a company that provides raw materials for pharmaceutical companies. The Company operates three product segments. The Steroid Raw Materials segment is engaged in the manufacturing of steroid raw materials using genetic engineering technology and microbial transformation technology, such as androstenedione, androstenedione, 9-hydroxyandrostenedione, hydroxyprogesterone and so on. The Company also operates Steroidal Finished Drug segment and Non-Steroidal Finished Drug segment through its subsidiary.
Sector
Pharmaceuticals
Calendar
2024-06-21
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
15.59
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.18% | 409M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- 300583 Stock
